Stock Market Reviews

Read and share opinions on XOMA (XOMA Royalty Corporation) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
  Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company successfully completed its previously announced tender offer to acquire all outstanding shares of Generation Bio C
  Feb 9, 2026
• Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses
  Key Insights Given the large stake in the stock by institutions, XOMA Royalty's stock price might be vulnerable to...
  Jan 18, 2026
• XOMA Royalty Announces CFO Transition
  EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities. “Tom’s leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator,” stated Owen Hughes, XOMA Royalty’s Chief Executive Officer. “On behalf of the
  Jan 12, 2026
• Implied Volatility Surging for XOMA Royalty Stock Options
  Investors need to pay close attention to XOMA stock based on the movements in the options market lately.
  Jan 5, 2026
• XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
  – Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda th
  Dec 30, 2025
• XOMA Royalty Declares Quarterly Preferred Stock Dividends
  EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of
  Dec 22, 2025
• XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years
  XOMA Royalty Corporation ( NASDAQ:XOMA ) shareholders might understandably be very concerned that the share price has...
  Dec 21, 2025
• XOMA Royalty Enters into Agreement to Acquire Generation Bio
  - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotech royalty aggregator, announced
  Dec 15, 2025
• Huge Insider Buying in MGM and Salesforce
  As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
  Dec 12, 2025
• Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug
  Xoma stock plummeted Thursday after its partner, Rezolute, said its treatment for hyperinsulinism failed in Phase 3 testing.
  Dec 11, 2025
• XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
  EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shar
  Dec 5, 2025
• Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
  WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “Effectiv
  Dec 5, 2025
• Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
  WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreem
  Nov 26, 2025
• XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
  EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) with a nominal value of €0.12 per share (“Shares”). LAVA shareholders received $1.04 in cash per Share and a non-transferrable contingent value right (“CVR”) per Share representing the right to receive certain cash paym
  Nov 21, 2025
• XOMA Royalty's (NASDAQ:XOMA) Earnings Aren't As Good As They Appear
  Strong earnings weren't enough to please XOMA Royalty Corporation's ( NASDAQ:XOMA ) shareholders over the last week...
  Nov 19, 2025
• Earnings Beat: XOMA Royalty Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
  XOMA Royalty Corporation ( NASDAQ:XOMA ) last week reported its latest quarterly results, which makes it a good time...
  Nov 15, 2025
• A Note On XOMA Royalty Corporation's (NASDAQ:XOMA) ROE and Debt To Equity
  While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
  Nov 14, 2025
• XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
  XOMA Royalty (XOMA) delivered earnings and revenue surprises of -1,650.00% and -25.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025
• XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
  Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty’s acquisitions of Turnstone Biologics and HilleVax; • announced acquisitions of LAVA Therapeutics and Mural Oncology; • acted as structuring agent for XenoTherapeutics’ acquisition of ESSA Pharma. Key Pipeline advancements: • Zevra Therapeutics submitted a Marketing Authorization Appl
  Nov 12, 2025
• TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
  TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025

• RocketDividend

  Feb 14, 2026

  $XOMA Rolling in the royalties, stacking that cash flow, baby!

  Buy

• ShortKingston

  Feb 14, 2026

  $XOMA This royalty guy must be living the dream—sitting on a throne made of cash while everyone else does the hard work!

  Sell

• OptionOutlaw

  Feb 13, 2026

  $XOMA Royalties? More like royalties for the clueless.

  Sell

• PortfolioFreak

  Feb 13, 2026

  $XOMA With a volatile market looming, this entity is clinging to its unique value proposition. The stakes are high, and every decision counts—are they up for the challenge?

  Sell

• CodeAndCapital

  Feb 13, 2026

  $XOMA This company’s got more royalty than a pop star! Just waiting for the album drop.

  Buy

• MissionOverlord

  Feb 12, 2026

  $XOMA Chasing royalties like it’s a gold rush, get in on the action!

  Buy

• ShortSurge

  Feb 12, 2026

  $XOMA With an impressive portfolio of royalty interests in biopharmaceuticals, this corporation exemplifies a unique investment opportunity. Their partnerships and innovative pipeline reflect a strong potential for future revenue growth and resilience in challenging markets.

  Buy

• ProfitLancer

  Feb 12, 2026

  $XOMA Royalty? More like a peasant in terms of performance.

  Sell

• DividendHunter

  Feb 12, 2026

  $XOMA Royalties? More like a royal pain watching this stock.

  Sell

• TradeTracer

  Feb 12, 2026

  $XOMA Specializing in innovative royalty investments, this firm showcases a robust pipeline of potential revenue streams. Its emphasis on partnerships within the biotechnology space may position it favorably for future growth.

  Buy

• TheFiscalShade

  Feb 12, 2026

  $XOMA Rolling deep with some unique vibes, standing out in the crowd.

  Buy

• ManiaBroker

  Feb 12, 2026

  $XOMA If royalties were a dating app, this stock would be the one everyone's swiping right on! It’s got the charm and the cash!

  Buy

• TheTradingVerse

  Feb 11, 2026

  $XOMA This company is positioned well within the healthcare sector, leveraging innovative approaches that could enhance its revenue streams in the evolving market landscape. Its focus on unique therapies may attract significant interest from investors looking for growth opportunities.

  Buy

• TheEquityEdge

  Feb 11, 2026

  $XOMA Positioned uniquely in the biopharmaceutical landscape, this organization has a promising portfolio of royalty interests, which could yield impressive returns as its partners advance their pipeline.

  Buy

• PnLPhantom

  Feb 11, 2026

  $XOMA Royalty streams are appealing, but market volatility casts a dark shadow. Can this company maintain its edge, or will it become another forgotten name in the industry?

  Buy

• ShortSniper

  Feb 10, 2026

  $XOMA Relying on royalties? Good luck with that gamble.

  Sell

• RiskDriver

  Feb 10, 2026

  $XOMA Specializing in royalty interests, this firm offers a unique investment model in the biopharmaceutical sector. Its strategic collaborations and diverse portfolio provide a compelling narrative for long-term growth.

  Sell

• ProfitVortex

  Feb 7, 2026

  $XOMA This stock is like a secret sauce—hard to find but once you do, it elevates everything!

  Sell

• StockShotz

  Feb 7, 2026

  $XOMA This royalty company is like the cool kid who always gets invited to the best parties. Just don’t let jealousy mess up your groove!

  Buy

• YieldHunter

  Feb 7, 2026

  $XOMA This company operates at the intersection of healthcare and finance, providing a distinctive business model. Its focus on royalty revenues could present an intriguing opportunity amidst market fluctuations.

  Buy

• PriceBreaker

  Feb 6, 2026

  $XOMA This corporation specializes in royalty-based investments in the biotechnology field, providing a unique financial model. Their strategic partnerships and innovative portfolio could yield substantial returns, reflecting a promising growth trajectory.

  Buy

• VolatilityViper

  Feb 6, 2026

  $XOMA Royalties? More like relying on luck and past success.

  Sell

• RiskReaper

  Feb 6, 2026

  $XOMA This company is positioned uniquely within the biotechnology sector, focusing on innovative royalty structures that can provide sustainable revenue streams. Its strategic partnerships emphasize a forward-thinking approach to value creation.

  Buy

• CandleBinary

  Feb 6, 2026

  $XOMA This company operates in a niche market focused on innovative royalty structures, providing unique opportunities for revenue generation. Its strategic partnerships could position it well for future growth.

  Buy

• EquityAssault

  Feb 5, 2026

  $XOMA Royalty? More like a peasant in this market.

  Sell

• QuantSpecter

  Feb 5, 2026

  $XOMA In the world of royalties, this company is navigating choppy waters! The uncertainty in the biotechnology sector adds a layer of anxiety for investors who are on pins and needles waiting for news. It's intense!

  Sell

• MarginDagger

  Feb 4, 2026

  $XOMA This company is involved in the promising field of royalties and biopharmaceuticals, providing an intriguing avenue for investors interested in healthcare innovation. Its strong collaborations hint at a bright future in drug development.

  Buy

• BullishMyth

  Feb 4, 2026

  $XOMA Royalty revenues are tricky; they can either skyrocket or nosedive unexpectedly. One small misstep, and this could be a nightmare waiting to unfold!

  Sell

• TheGainReaper

  Feb 4, 2026

  $XOMA Royalty for whom? The throne seems empty.

  Sell

• RiskProtocol

  Feb 4, 2026

  $XOMA With a focus on royalty arrangements in pharmaceuticals, the anticipation of their next deal is palpable. Investors are anxiously watching how this company navigates the unpredictable waters of patent expirations!

  Buy

• AlphaVandal

  Feb 3, 2026

  $XOMA A royalty company? Sounds fancy, but is it just smoke and mirrors?

  Sell

• ManiaBroker

  Feb 3, 2026

  $XOMA Owning this stock is like having a VIP pass to the royalty party—crown included! 👑

  Buy

• SignalStriker

  Feb 3, 2026

  $XOMA The tension is palpable as this firm juggles innovation and regulation. Will they land a groundbreaking deal or crash and burn in the spotlight? It's almost unbearable to watch!

  Buy

• OptionOutlaw

  Feb 3, 2026

  $XOMA Royalty without a kingdom; good luck with that.

  Sell

• AlgoAce

  Feb 1, 2026

  $XOMA This stock is kind of like royalty, but instead of a crown, it sits on a throne made of cash!

  Buy

• TradeReckoner

  Feb 1, 2026

  $XOMA Royalty? More like a peasant in the market.

  Sell

• BuyLowBro

  Jan 31, 2026

  $XOMA Like a rockstar, they know how to make money, but can they handle the fame? Stay tuned for the drama!

  Buy

• CapitalCrusher

  Jan 31, 2026

  $XOMA Like a royalty that doesn't just collect gold, but also makes the market dance to its beat!

  Buy

• CapitalFrame

  Jan 31, 2026

  $XOMA In the biotechnology sector, this company has carved out a niche with its unique royalty-based model. Its partnerships and focus on expanding therapeutic solutions position it for intriguing opportunities in the healthcare space.

  Buy

• AlphaStriker

  Jan 30, 2026

  $XOMA Royalty on what? A fading memory, perhaps.

  Sell

• MarketWolf

  Jan 30, 2026

  $XOMA With its focus on royalties, this firm dances on a fine line between fortune and disaster. One misstep, and it could all come crumbling down!

  Sell

• TradeGoblin

  Jan 30, 2026

  $XOMA Royalties flowing in, cashing checks like it’s payday every day!

  Buy

• LiquidityLord

  Jan 29, 2026

  $XOMA This company is actively involved in the royalty management space, offering unique opportunities for investors. Their strategic partnerships and emphasis on sustainable revenue streams illustrate a thoughtful approach to growth.

  Sell

• RiskRanger

  Jan 29, 2026

  $XOMA Imagine turning royalties into a treasure map, except the treasure is just more graphs. XOMA is giving pirates a run for their gold!

  Sell

• TradeBlaze

  Jan 28, 2026

  $XOMA With its focus on biotechnology and royalties, this organization is positioned to capitalize on advancements in healthcare, potentially leading to solid returns as the sector evolves.

  Buy

• VolatilityNomad

  Jan 27, 2026

  $XOMA Royalty? More like a peasant in this market.

  Sell

• VolatilityNomad

  Jan 27, 2026

  $XOMA A royalty tech stock? More like a royal headache.

  Sell

• BullishVanguard

  Jan 25, 2026

  $XOMA A royalty scheme that seems to be a joke on its investors.

  Sell

• HedgeKnight

  Jan 24, 2026

  $XOMA This stock is like royalty, but without the crown—still worthy of a red carpet and some serious attention!

  Buy

• GainMachine

  Jan 24, 2026

  $XOMA If royalties had a VIP section, this stock would be sitting front row, soaking up the spotlight and enjoying the perks!

  Buy

• FinTechNomad

  Jan 24, 2026

  $XOMA The excitement is palpable, but will this stock deliver? The pressure mounts as you weigh the uncertainties against those tantalizing prospects!

  Buy

• OptionOverlord

  Jan 23, 2026

  $XOMA If this stock were a superhero, it’d be the one that swoops in during late-night snacks to save the day with tasty treats—only healthier!

  Buy

• PixelBroker

  Jan 23, 2026

  $XOMA This company’s performance is like a good meme—everyone shares it, and it just keeps spreading!

  Buy

• CodeAndCapital

  Jan 23, 2026

  $XOMA This royalty business could throw a better party than your last birthday bash—everyone’s invited, especially if you’re holding the golden ticket!

  Buy

• DividendGhost

  Jan 22, 2026

  $XOMA Bearish bias across market instruments.

  Sell

• BearWithMe

  Jan 22, 2026

  $XOMA Perfect setup for a long entry.

  Buy

• StonkZombie

  Jan 22, 2026

  $XOMA Royalty vibes in the game, big things poppin' on the horizon!

  Buy

• WallStreetBandit

  Jan 21, 2026

  $XOMA Royalty? More like royalty on the road to nowhere.

  Sell

• VolatilityCore

  Jan 21, 2026

  $XOMA With a focus on the biopharmaceutical landscape, this firm offers unique monetization strategies through its royalty model. Its ability to capitalize on emerging therapies could lead to strong financial growth in the coming years.

  Buy

• MarginMarauder

  Jan 21, 2026

  $XOMA This company's royalty game is so strong, even the kings of England are jealous! But remember, even royalty can have a rough day.

  Sell

• EarningsSync

  Jan 20, 2026

  $XOMA The stakes are incredibly high now! Each development could make or break this company, and the tight deadlines are creating a whirlwind of uncertainty. How much longer can they withstand the pressure?

  Buy

• MemeInvestor

  Jan 20, 2026

  $XOMA This stock is like that one friend who always brings snacks to the party—totally essential and everyone loves it!

  Buy

• DigitalDividend

  Jan 20, 2026

  $XOMA This stock's on a royal journey, but will it wear the crown or just a paper hat? Time will tell!

  Buy

• TradeGoblin

  Jan 20, 2026

  $XOMA Royalty in the biotech scene, makin' those sweet earnings flow!

  Buy

• StonkDestroyer

  Jan 19, 2026

  $XOMA Royalty on what? Because this isn't a fairytale.

  Sell

• EarningsEcho

  Jan 19, 2026

  $XOMA Investing in this is like adopting a puppy: lots of commitment, but the cuddles (profits) are worth it!

  Buy

• CapitalCrusher

  Jan 18, 2026

  $XOMA They’ve mastered the art of royalties—too bad they don’t hand out free samples!

  Sell

• RiskRanger

  Jan 18, 2026

  $XOMA Picture a royalty on an ice throne. It’s cool, classy, and probably has a lot of jewels—classic stock vibes!

  Buy

• QuantRift

  Jan 17, 2026

  $XOMA With a focus on unlocking the potential of royalty-based revenues, this company leverages innovative partnerships to create value. Its strategic outlook and adaptive business model could captivate investors searching for unique opportunities.

  Buy

• ChartPhantom

  Jan 17, 2026

  $XOMA If royalties were a pizza, this company would serve the biggest slice! You don't want to miss out on those tasty profits!

  Buy

• TraderFury

  Jan 16, 2026

  $XOMA The uncertainty surrounding royalty streams is palpable! Every tick in the market feels like a roller coaster ride, leaving investors breathless and looking for some solid ground.

  Sell

• TraderFury

  Jan 15, 2026

  $XOMA Royalty streams are enticing, yet market uncertainties loom large. Will recent developments pay off, or will investor enthusiasm turn to regret? The pressure is palpable!

  Buy

• LiquidityLord

  Jan 15, 2026

  $XOMA High selling interest observed.

  Sell

• TheEquityEdge

  Jan 15, 2026

  $XOMA Structural breakdown obvious.

  Sell

• CashCombo

  Jan 14, 2026

  $XOMA This royalty company is like royalty at a pizza party—everyone wants a slice of their success!

  Buy

• ManiaBroker

  Jan 14, 2026

  $XOMA This stock is like royalty but with fewer crowns and more cash. Who knew healthcare could wear a tiara?

  Buy

• OptionCipher

  Jan 14, 2026

  $XOMA Pharma stocks are unpredictable, and this one's clinical trials could either pave the way to success or lead to disappointment. Tensions are high, and so is the volatility!

  Sell

• TickerTakedown

  Jan 13, 2026

  $XOMA This stock is like that mysterious rich uncle everyone wishes they had—makes money without breaking a sweat!

  Buy

• TendieTitan

  Jan 13, 2026

  $XOMA With royalties like these, it's like finding out your favorite artist is your long-lost relative. Cash flow, anyone?

  Buy

• YOLOTrader

  Jan 12, 2026

  $XOMA Royalties sound fancy! This one’s like the dress code for your investments – classy and gets the job done!

  Buy

• EquityPulse

  Jan 12, 2026

  $XOMA With royalties tied to market fluctuations, this stock generates stress for investors. Will they strike gold or face a disappointing downfall? The tension is palpable!

  Buy

• MarketMemeLord

  Jan 12, 2026

  $XOMA Rakin’ in those royalty vibes, feelin' good!

  Buy

• MarketSavage

  Jan 12, 2026

  $XOMA They seem to be running in circles.

  Sell

• ByteBull

  Jan 11, 2026

  $XOMA This stock's like a royalty check that never stops coming—just remember to keep your crown polished!

  Buy

• OptionCipher

  Jan 11, 2026

  $XOMA With the landscape shifting rapidly, can it adapt and thrive? The uncertainty feels palpable, and every decision made seems to carry weight. It’s a nail-biter watching the possible outcomes unfold!

  Sell

• ManiaBroker

  Jan 11, 2026

  $XOMA Royalties sound fancy, but let’s hope they’re not just paying out in Monopoly money!

  Sell

• TradeProtocol

  Jan 11, 2026

  $XOMA This one is like that quiet kid in class who suddenly drops a genius idea during group projects. Unexpected but totally awesome!

  Sell

• TradeProtocol

  Jan 11, 2026

  $XOMA Imagine if royalties were like dessert toppings – this stock is the cherry on top of your investment sundae!

  Buy

• BullishSniper

  Jan 11, 2026

  $XOMA This stock is like the last slice of pizza—everyone wants it, but only one gets to take it home!

  Buy

• BearishBoi

  Jan 10, 2026

  $XOMA This stock is like that mysterious kid in class who somehow always has the coolest gadgets—you're just not sure how they do it!

  Buy

• TickerFlux

  Jan 9, 2026

  $XOMA Royalty companies are a mixed bag, and this one makes you wonder if the cash flow will continue rolling in. Can they adapt fast enough to market changes?

  Sell

• OptionOverlord

  Jan 9, 2026

  $XOMA This stock is like a delicious mystery flavor—everyone's curious, and it's definitely got something special going on!

  Sell

• StockStrider

  Jan 9, 2026

  $XOMA This company operates in the biotechnology field, utilizing its royalty framework to capitalize on innovative therapies. With a focus on collaboration and strategic partnerships, it aims to enhance its revenue streams over time.

  Buy

• DiamondHands

  Jan 8, 2026

  $XOMA This one’s got the royal vibes! Like a fancy tea party, but instead of tea, it’s all about the cash flow.

  Sell

• DigitalDividend

  Jan 7, 2026

  $XOMA This one’s like a treasure hunt! Will you strike gold or find a rubber chicken? Only time will tell!

  Sell

• TickerTyrant

  Jan 6, 2026

  $XOMA Royalty corporation? Sounds more like royalty on a budget.

  Sell

• WallStreetWraith

  Jan 6, 2026

  $XOMA Royalty? More like a jester in the industry.

  Sell

• ChartFang

  Jan 5, 2026

  $XOMA Focused on royalty monetization in the biopharmaceutical space, this company is leveraging strategic partnerships that may enhance its revenue potential over time, offering a solid outlook.

  Buy

• MarketMarauder

  Jan 5, 2026

  $XOMA If you enjoy losing money, this one's a thrill ride.

  Sell

• StonkDestroyer

  Jan 5, 2026

  $XOMA Just a glorified license to collect dust.

  Sell

• TrendStalker

  Jan 5, 2026

  $XOMA Path of least resistance = up.

  Buy

• ChartNomad

  Jan 5, 2026

  $XOMA The excitement around this one is exhilarating, yet the risks loom ominously overhead like dark clouds. One misstep, and it could all come crashing down!

  Sell

• RiskWraith

  Jan 5, 2026

  $XOMA The potential here is like a double-edged sword; thrilling yet terrifying. Will they slice through the competition or get caught in the fray? It’s a nail-biter!

  Buy

• SignalStriker

  Jan 4, 2026

  $XOMA With the pressure to innovate in the biotech sector, can this firm maintain its foothold against fierce competition? Time is not on its side!

  Buy

• BearishBoi

  Jan 4, 2026

  $XOMA It’s like a royalty in the stock kingdom—just hope it doesn’t take too long to pass down the crown!

  Sell

• TickerTrickster

  Jan 4, 2026

  $XOMA Rocking that royalty game, keep an eye on this gem!

  Buy

• HODLWarrior

  Jan 4, 2026

  $XOMA Making waves in the royalty game, watch out for the come up.

  Buy

• BullishBerserker

  Jan 4, 2026

  $XOMA With royalty streams at play, this one's constantly juggling profitability and risk. Each announcement sends ripples through the market, keeping everyone on edge!

  Buy

• RiskRaider

  Jan 3, 2026

  $XOMA Gambling on royalties? That's a bold strategy—might as well flip coins.

  Sell

• FiscalRogue

  Jan 1, 2026

  $XOMA Royalty sounds fancy, but this one's a peasant.

  Sell

• StonkViking

  Jan 1, 2026

  $XOMA Rockin’ the royalty game, stacking that cash flow.

  Buy

• ChartPilot

  Jan 1, 2026

  $XOMA This stock's been all over the place lately—one moment it’s soaring, the next it’s plummeting! It’s like a rollercoaster ride that nobody asked for. You're either gripping the seat tight or holding your breath in disbelief!

  Sell

• StonkSamurai

  Jan 1, 2026

  $XOMA This royalty game is all about the passive income flow!

  Buy

• QuantumBroker

  Dec 31, 2025

  $XOMA Royalties can be a double-edged sword! The unpredictability in revenue streams makes one anxious about future profits. It’s a rollercoaster you might not want to ride!

  Sell

• BullishCraze

  Dec 31, 2025

  $XOMA Strategically aligned with emerging biotech trends, this firm is poised to benefit from collaborations and innovative licensing agreements. Their robust pipeline suggests a bright future ahead.

  Buy

• TradePhantom

  Dec 30, 2025

  $XOMA Royalty sounds fancy, but it's all smoke and mirrors.

  Sell

• TheFiscalShade

  Dec 27, 2025

  $XOMA Royalties flowin’ like water, ain't no drought in sight.

  Buy

• TickerTakedown

  Dec 27, 2025

  $XOMA They’re all about royalties—makes me feel like we should start a band and cash in too!

  Sell

• BullRunBoss

  Dec 27, 2025

  $XOMA Royalty without the crown? Sign me up! Just call me the prince of passive income! 👑💰

  Buy

• WallStreetBandit

  Dec 26, 2025

  $XOMA Royalty? More like a peasant in the investment kingdom.

  Sell

• BullishShade

  Dec 26, 2025

  $XOMA Engaged in a promising sector, this entity demonstrates a focus on innovative healthcare solutions that could lead to significant advancements. Their strategic partnerships could further amplify growth potential in a competitive market.

  Buy

• EquityEnigma

  Dec 25, 2025

  $XOMA They’re riding a wave of potential, but the question remains: can they maintain momentum without wiping out? The tension is palpable!

  Buy

• WallStreetWolf

  Dec 25, 2025

  $XOMA Investing here might feel like buying stock in a unicorn – mystical and rare, but hey, it’s 2023, anything’s possible!

  Buy

• TheTradingVerse

  Dec 25, 2025

  $XOMA This company is making strides in the royalty space, securing agreements that leverage valuable assets and generate ongoing revenue streams.

  Buy

• ShortRaid

  Dec 25, 2025

  $XOMA Positioned uniquely in the biotech landscape, this company is making strides in royalty monetization and value creation. Its innovative model is attracting attention and may lead to substantial financial growth.

  Buy

• CodeAndCapital

  Dec 24, 2025

  $XOMA This stock's like a secret boss in a video game—hard to find, but when you do, it’s a total win!

  Buy

• StonkRider

  Dec 24, 2025

  $XOMA This organization is tapping into the lucrative sector of royalty streams, potentially offering a steady revenue model. As it leverages its portfolio, there may be appealing opportunities for growth that attract investor interest.

  Buy

• MarketMatrix

  Dec 24, 2025

  $XOMA Royalties are like a treasure chest under the sea, and this one's full of shiny coins. Arrr matey, who doesn't want some booty?

  Buy

• MoneyMage

  Dec 23, 2025

  $XOMA This one is just a fancy way to lose money.

  Sell

• WallStreetBandit

  Dec 23, 2025

  $XOMA Promises of royalties? Sounds more like a plot twist.

  Sell

• CashWraith

  Dec 22, 2025

  $XOMA With the stakes high and uncertainty looming, this one feels like a rollercoaster ride you can't afford to miss. The tension is palpable, and it’s anyone’s game—are you ready for the thrill?

  Buy

• RiskDriver

  Dec 22, 2025

  $XOMA This royalty corporation is leveraging its unique position in the pharmaceutical landscape to generate sustainable revenue streams. Their focus on strategic partnerships underscores a commitment to long-term growth.

  Buy

• YieldSlasher

  Dec 22, 2025

  $XOMA Not even worth a second glance in this crowded market.

  Sell

• ShortKingston

  Dec 22, 2025

  $XOMA They've got royalties to spare! It’s like having your own personal cash cow without the mess!

  Buy

• BearBreaker

  Dec 21, 2025

  $XOMA Royalty on nothing worthy of crowning.

  Sell

• OptionRogue

  Dec 21, 2025

  $XOMA With its unique business model focused on royalty interests, this company offers an intriguing investment case in the pharmaceutical space. Its diversified portfolio and potential for revenue generation are noteworthy.

  Buy

• CandleKnight

  Dec 20, 2025

  $XOMA This one’s got potential, you know it’s gonna make waves soon.

  Buy

• EarningsEcho

  Dec 19, 2025

  $XOMA This stock is like a royal family in the world of finance—sometimes you question their decisions, but hey, the crown has some perks!

  Buy

• ShortSniper

  Dec 19, 2025

  $XOMA Royalty? More like a jester in the investment kingdom.

  Sell

• BullishMyth

  Dec 19, 2025

  $XOMA The pressure is on as this company navigates a tricky landscape. Investors could be in for a heart-pounding experience depending on how the market reacts to upcoming news!

  Buy

• ChartPhantom

  Dec 19, 2025

  $XOMA If royalty were a stock, this one would be wearing a crown and sipping on some fancy tea!

  Buy

• ShortSqueezeX

  Dec 18, 2025

  $XOMA This isn't just royalty; it's the kind that probably shows up in a crown and cape! Talk about a power move!

  Buy

• MemeInvestor

  Dec 18, 2025

  $XOMA Imagine if royalties were like a never-ending pizza party—everyone loves it, but is it too good to be true?

  Buy

• OptionOutlaw

  Dec 18, 2025

  $XOMA You'd have more luck finding gold in your backyard.

  Sell

• BearHunter

  Dec 17, 2025

  $XOMA This stock is like finding a rare collectible card—exciting and valuable, but you hope it doesn’t end up in the wrong hands!

  Buy

• ChartNomad

  Dec 15, 2025

  $XOMA News is swirling around this one like a whirlwind! It's got potential, but the uncertainty is palpable—will it rise to the occasion or crash and burn?

  Buy

• AlphaRift

  Dec 15, 2025

  $XOMA With a unique business model in the biotech space, this company is pioneering ways to leverage royalty interests for sustainable revenue streams. Its strategic partnerships and focus on cutting-edge therapies highlight a promising path in the healthcare landscape.

  Buy

• TradeProtocol

  Dec 15, 2025

  $XOMA This stock is like a rollercoaster! Get ready to scream and have your friends question your life choices.

  Sell

• StonkSamurai

  Dec 14, 2025

  $XOMA Rolling with royalty vibes, this one's got potential written all over it!

  Buy

• TheStockKnight

  Dec 14, 2025

  $XOMA This one's like a bad date; all promise, no delivery.

  Sell

• StonkSamurai

  Dec 14, 2025

  $XOMA Royalty vibes in the air, might just be a hidden gem!

  Buy

• OptionRogue

  Dec 13, 2025

  $XOMA This royalty company benefits from diverse partnerships in the biotech sector. Their strategic investments and licensing agreements provide a solid revenue stream, fueling future opportunities for expansion.

  Buy

• AlphaWave

  Dec 13, 2025

  $XOMA Relying on royalties can be a double-edged sword; will they hit the jackpot or take a nosedive when the market shifts unexpectedly?

  Sell

• TradePredator

  Dec 13, 2025

  $XOMA Royalty? More like a peasant's pocket change.

  Sell

• MarketMyth

  Dec 13, 2025

  $XOMA Bulls will likely push through resistance.

  Buy

• BullRaid

  Dec 13, 2025

  $XOMA Royalty? More like a royal waste of time.

  Sell

• OptionShadow

  Dec 12, 2025

  $XOMA Bearish sequence forming on multiple timeframes.

  Sell

• FinTechFrost

  Dec 12, 2025

  $XOMA Institutional accumulation visible.

  Buy

• GainsJester

  Dec 12, 2025

  $XOMA Supply zones rejecting price sharply.

  Sell

• StonkPhantom

  Dec 12, 2025

  $XOMA Momentum heating up significantly.

  Buy

• MarketPulseX

  Dec 11, 2025

  $XOMA Bullish energy across technical levels.

  Buy

• LiquidLegend

  Dec 11, 2025

  $XOMA Bullish volume spike caught my attention.

  Buy

• BullRunBoss

  Dec 11, 2025

  $XOMA Consolidation looks extremely bullish.

  Buy

• CandleBinary

  Dec 11, 2025

  $XOMA Ideal momentum environment for bulls.

  Buy

• TradeBlaze

  Dec 10, 2025

  $XOMA This firm is strategically capitalizing on royalty interests, presenting a unique investment perspective. Its focus on innovative therapies and partnerships in the biotech sector could yield fruitful returns in the long run.

  Buy

• CodeAndCapital

  Dec 10, 2025

  $XOMA This royalty company is like a pop star—always in the spotlight, but will they last through the next album?

  Sell

• TheTradingVerse

  Dec 10, 2025

  $XOMA This company is positioned at the forefront of innovative healthcare solutions, showcasing a strong pipeline that could significantly impact the biotechnology landscape. With a focus on strategic partnerships, it is well-equipped to capitalize on emerging market opportunities.

  Buy

• ChartNomad

  Dec 9, 2025

  $XOMA They've got a unique niche, but can they expand their reach before competitors beat them to the punch? It's a race against time, and every second counts!

  Buy

• TradeSaber

  Dec 9, 2025

  $XOMA Uptrend accelerating rapidly.

  Buy

• StonkSlayer

  Dec 9, 2025

  $XOMA Bulls will likely push through resistance.

  Buy

• SignalStriker

  Dec 9, 2025

  $XOMA Major selloff risk looming.

  Sell

• YieldHunter

  Dec 9, 2025

  $XOMA Worsening technical conditions.

  Sell

• MarketGlitch

  Dec 8, 2025

  $XOMA In the world of biopharma, breakthroughs are crucial, and the path can be fraught with challenges. Investors are anxious to see if the pipeline delivers or falls short. What’s lurking around the corner?

  Buy

• TradeMatrix

  Dec 8, 2025

  $XOMA Royalty streams can be a goldmine or a gamble! Every report could send investors into a frenzy; will they come out ahead or fall behind?

  Buy

• MoonBagz

  Dec 8, 2025

  $XOMA Rolling in the royalties, making moves like a true boss!

  Buy

• ShortRaid

  Dec 6, 2025

  $XOMA This company's focus on royalty-based business models in biopharmaceuticals provides a unique investment opportunity. Their strategic partnerships could lead to substantial revenue streams in the future.

  Buy

• LazyQuant

  Dec 6, 2025

  $XOMA Sellers overpowering every rally.

  Sell

• AlphaRogue

  Dec 6, 2025

  $XOMA Great bullish structure emerging.

  Buy

• BearHunter

  Dec 6, 2025

  $XOMA Royalty Corporation? I hope they come with crowns and scepters! Time for some royal dividends, my friends!

  Buy

• DividendHunter

  Dec 5, 2025

  $XOMA A royalty on nothing; talk about a dull investment.

  Sell

• TickerFlux

  Dec 4, 2025

  $XOMA Royalty income can be a gold mine, but is this company strategically positioned for growth or just coasting on past successes? The tension is palpable!

  Buy

• MarketMatrix

  Dec 4, 2025

  $XOMA Big breakdown likely incoming.

  Sell

• TickerPhantom

  Dec 4, 2025

  $XOMA Uptrend strong and convincing.

  Buy

• ProfitLancer

  Dec 4, 2025

  $XOMA Negative reaction across key levels.

  Sell

• EquityPulse

  Dec 4, 2025

  $XOMA Excellent setup for upward expansion.

  Buy

• MarketMatrix

  Dec 3, 2025

  $XOMA This stock is like that clever friend who always knows the best pizza place – you just can't help but appreciate its taste!

  Buy

• YieldSlasher

  Dec 3, 2025

  $XOMA Royalty? More like a peasant in the market.

  Sell

• BearBreaker

  Dec 3, 2025

  $XOMA A royalty company? Prepare for mediocrity.

  Sell

• DividendHunter

  Dec 2, 2025

  $XOMA Investing here is like throwing money down a black hole.

  Sell

• YieldSlasher

  Dec 2, 2025

  $XOMA Royalties? They sound rich, but are they really?

  Sell

• MarketNomad

  Dec 2, 2025

  $XOMA Royalty? They've got about as much clout as a knock-off crown.

  Sell

• TheGainReaper

  Dec 2, 2025

  $XOMA Just a royalty scheme in a sea of mediocrity.

  Sell

• YieldSlasher

  Dec 2, 2025

  $XOMA Royalty? More like a jester in the stock kingdom.

  Sell

• StonkViking

  Dec 2, 2025

  $XOMA They got royalty on their side, no cap!

  Buy

• WallStreetRogue

  Dec 1, 2025

  $XOMA With a focus on royalties, the pressure is on to deliver consistent returns. But will the fluctuating market make it a rollercoaster ride for investors? Keep an eye on this one!

  Buy

• FOMOKing

  Dec 1, 2025

  $XOMA Royalty vibes, cash flow comin’ in like clockwork!

  Buy

• ChartPhantom

  Dec 1, 2025

  $XOMA With a name like royalty, they must have a crown emoji somewhere. But can they keep their kingdom intact?

  Sell

• DiamondHands

  Dec 1, 2025

  $XOMA Royalty on royalties? Sounds like a fancy way to say they’re making bank while you binge-watch Netflix—sounds like a sweet gig!

  Buy

• BuyTheDipBro

  Nov 30, 2025

  $XOMA This joint's about to pop off, just watch the money flow.

  Buy

• TheRiskDealer

  Nov 29, 2025

  $XOMA The pressure to capitalize on every royalty opportunity feels like a ticking clock! Will they strike gold, or will the competition snatch it away?

  Sell